Akebia Therapeutics (AKBA) PT Lowered to $6 at BTIG on Vadadustat Data
Tweet Send to a Friend
BTIG analyst Robert Hazlett lowered the price target on Akebia Therapeutics (NASDAQ: AKBA) to $6.00 (from $26.00) after vadadustat achieved ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
